590 related articles for article (PubMed ID: 12975286)
1. Cerebrospinal fluid markers in dementia with lewy bodies compared with Alzheimer disease.
Gómez-Tortosa E; Gonzalo I; Fanjul S; Sainz MJ; Cantarero S; Cemillán C; Yébenes JG; del Ser T
Arch Neurol; 2003 Sep; 60(9):1218-22. PubMed ID: 12975286
[TBL] [Abstract][Full Text] [Related]
2. Cerebrospinal fluid biomarkers in Parkinson's disease with dementia and dementia with Lewy bodies.
Parnetti L; Tiraboschi P; Lanari A; Peducci M; Padiglioni C; D'Amore C; Pierguidi L; Tambasco N; Rossi A; Calabresi P
Biol Psychiatry; 2008 Nov; 64(10):850-5. PubMed ID: 18395699
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.
Tapiola T; Alafuzoff I; Herukka SK; Parkkinen L; Hartikainen P; Soininen H; Pirttilä T
Arch Neurol; 2009 Mar; 66(3):382-9. PubMed ID: 19273758
[TBL] [Abstract][Full Text] [Related]
4. Serum heart-type fatty acid-binding protein and cerebrospinal fluid tau: marker candidates for dementia with Lewy bodies.
Mollenhauer B; Steinacker P; Bahn E; Bibl M; Brechlin P; Schlossmacher MG; Locascio JJ; Wiltfang J; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Neurodegener Dis; 2007; 4(5):366-75. PubMed ID: 17622779
[TBL] [Abstract][Full Text] [Related]
5. Cerebrospinal fluid total tau is associated with shorter survival in dementia with Lewy bodies.
Boström F; Hansson O; Blennow K; Gerhardsson L; Lundh T; Minthon L; Zetterberg H; Londos E
Dement Geriatr Cogn Disord; 2009; 28(4):314-9. PubMed ID: 19844105
[TBL] [Abstract][Full Text] [Related]
6. Measurement of phosphorylated tau epitopes in the differential diagnosis of Alzheimer disease: a comparative cerebrospinal fluid study.
Hampel H; Buerger K; Zinkowski R; Teipel SJ; Goernitz A; Andreasen N; Sjoegren M; DeBernardis J; Kerkman D; Ishiguro K; Ohno H; Vanmechelen E; Vanderstichele H; McCulloch C; Moller HJ; Davies P; Blennow K
Arch Gen Psychiatry; 2004 Jan; 61(1):95-102. PubMed ID: 14706948
[TBL] [Abstract][Full Text] [Related]
7. CSF alpha-synuclein levels in dementia with Lewy bodies and Alzheimer's disease.
Noguchi-Shinohara M; Tokuda T; Yoshita M; Kasai T; Ono K; Nakagawa M; El-Agnaf OM; Yamada M
Brain Res; 2009 Jan; 1251():1-6. PubMed ID: 19071095
[TBL] [Abstract][Full Text] [Related]
8. Cerebrospinal fluid tau and beta-amyloid: how well do these biomarkers reflect autopsy-confirmed dementia diagnoses?
Clark CM; Xie S; Chittams J; Ewbank D; Peskind E; Galasko D; Morris JC; McKeel DW; Farlow M; Weitlauf SL; Quinn J; Kaye J; Knopman D; Arai H; Doody RS; DeCarli C; Leight S; Lee VM; Trojanowski JQ
Arch Neurol; 2003 Dec; 60(12):1696-702. PubMed ID: 14676043
[TBL] [Abstract][Full Text] [Related]
9. Glucose hypometabolism and neuropathological correlates in brains of dementia with Lewy bodies.
Higuchi M; Tashiro M; Arai H; Okamura N; Hara S; Higuchi S; Itoh M; Shin RW; Trojanowski JQ; Sasaki H
Exp Neurol; 2000 Apr; 162(2):247-56. PubMed ID: 10739631
[TBL] [Abstract][Full Text] [Related]
10. Validation of amyloid-beta peptides in CSF diagnosis of neurodegenerative dementias.
Bibl M; Mollenhauer B; Lewczuk P; Esselmann H; Wolf S; Trenkwalder C; Otto M; Stiens G; Rüther E; Kornhuber J; Wiltfang J
Mol Psychiatry; 2007 Jul; 12(7):671-80. PubMed ID: 17339876
[TBL] [Abstract][Full Text] [Related]
11. CSF tau, Aβ42, and MHPG differentiate dementia with Lewy bodies from Alzheimer's disease.
Aerts MB; Esselink RA; Claassen JA; Abdo WF; Bloem BR; Verbeek MM
J Alzheimers Dis; 2011; 27(2):377-84. PubMed ID: 21841257
[TBL] [Abstract][Full Text] [Related]
12. CSF amyloid-β peptides in neuropathologically diagnosed dementia with Lewy bodies and Alzheimer's disease.
Mollenhauer B; Esselmann H; Trenkwalder C; Schulz-Schaeffer W; Kretzschmar H; Otto M; Wiltfang J; Bibl M
J Alzheimers Dis; 2011; 24(2):383-91. PubMed ID: 21297274
[TBL] [Abstract][Full Text] [Related]
13. Amyloid pathology influences aβ1-42 cerebrospinal fluid levels in dementia with lewy bodies.
Slaets S; Le Bastard N; Theuns J; Sleegers K; Verstraeten A; De Leenheir E; Luyckx J; Martin JJ; Van Broeckhoven C; Engelborghs S
J Alzheimers Dis; 2013; 35(1):137-46. PubMed ID: 23364139
[TBL] [Abstract][Full Text] [Related]
14. CSF α-synuclein does not discriminate dementia with Lewy bodies from Alzheimer's disease.
Reesink FE; Lemstra AW; van Dijk KD; Berendse HW; van de Berg WD; Klein M; Blankenstein MA; Scheltens P; Verbeek MM; van der Flier WM
J Alzheimers Dis; 2010; 22(1):87-95. PubMed ID: 20847452
[TBL] [Abstract][Full Text] [Related]
15. Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.
Mollenhauer B; Cepek L; Bibl M; Wiltfang J; Schulz-Schaeffer WJ; Ciesielczyk B; Neumann M; Steinacker P; Kretzschmar HA; Poser S; Trenkwalder C; Otto M
Dement Geriatr Cogn Disord; 2005; 19(2-3):164-70. PubMed ID: 15637452
[TBL] [Abstract][Full Text] [Related]
16. Anomalously phosphorylated tau and Abeta fragments in the CSF correlates with cognitive impairment in MCI subjects.
Maccioni RB; Lavados M; Guillón M; Mujica C; Bosch R; Farías G; Fuentes P
Neurobiol Aging; 2006 Feb; 27(2):237-44. PubMed ID: 16399209
[TBL] [Abstract][Full Text] [Related]
17. Improved discrimination of autopsy-confirmed Alzheimer's disease (AD) from non-AD dementias using CSF P-tau(181P).
Koopman K; Le Bastard N; Martin JJ; Nagels G; De Deyn PP; Engelborghs S
Neurochem Int; 2009 Sep; 55(4):214-8. PubMed ID: 19524111
[TBL] [Abstract][Full Text] [Related]
18. Correlations of CSF tau and amyloid levels with Alzheimer pathology in neuropathologically verified dementia with Lewy bodies.
Brunnström H; Hansson O; Zetterberg H; Londos E; Englund E
Int J Geriatr Psychiatry; 2013 Jul; 28(7):738-44. PubMed ID: 22911491
[TBL] [Abstract][Full Text] [Related]
19. Interleukin-12 is reduced in cerebrospinal fluid of patients with Alzheimer's disease and frontotemporal dementia.
Rentzos M; Paraskevas GP; Kapaki E; Nikolaou C; Zoga M; Rombos A; Tsoutsou A; Vassilopoulos D D
J Neurol Sci; 2006 Nov; 249(2):110-4. PubMed ID: 16843497
[TBL] [Abstract][Full Text] [Related]
20. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele.
Smach MA; Charfeddine B; Lammouchi T; Harrabi I; Ben Othman L; Dridi H; Bennamou S; Limem K
Neurosci Lett; 2008 Aug; 440(2):145-9. PubMed ID: 18555606
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
